MedPath

Actual Use Trial of Ibuprofen 400 mg

Phase 3
Completed
Conditions
Patient Compliance
Interventions
Registration Number
NCT02294019
Lead Sponsor
Pfizer
Brief Summary

This is an open label, multicenter, 30 day study designed to mimic an OTC like environment in which subjects will use the product after making a purchase decision about ibuprofen 400 mg caplets based only on their reading of the Drug Facts Label (DFL) and other information on the package.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
738
Inclusion Criteria
  • Male or female at least 18 years of age (19 years of age in Alabama)
  • Subject reports taking over-the-counter (OTC) analgesics for pain or fever relief
Exclusion Criteria
  • Current government-issued identification (ID)
  • Pregnant or breastfeeding females

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Ibuprofen caplet armIbuprofen 400 mg caplet-
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the StudyDay 1 up to 30 days

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants took more than 1200 mg (\>3 caplets) on either 0, 1 or 2 use days (where a use day was defined as a calendar day starting at 12:01 AM in which a participant received at least one dose of study medication), based on their diary. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking more than 3 caplets per day, under the advice of a healthcare professional, based on information from the end of study follow-up interview.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Taking Greater Than (>) 400 mg (>1 Caplet) at a Time on no More Than 2 Dosing Occasions During the StudyDay1 up to 30 days

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if the total number of dosing occasions (distinct usage date/time values from their diary) in which a participant received 2 or more caplets was 0, 1 or 2. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking no more than 1 caplet per dose, under the advice of a healthcare professional, based on the end of study follow up interview.

Trial Locations

Locations (22)

Community Clinical Pharmacy

🇺🇸

Mesa, Arizona, United States

Family Plaza Pharmacy

🇺🇸

West Jordan, Utah, United States

Robert's Discount Pharmacy

🇺🇸

Hoover, Alabama, United States

Pharmacy at the Pig

🇺🇸

McCalla, Alabama, United States

Garden Drug

🇺🇸

Fort Lauderdale, Florida, United States

Sutton Family Pharmacy

🇺🇸

Dalton, Georgia, United States

Pill Box Pharmacy and Medical Supply

🇺🇸

Pembroke Pines, Florida, United States

Wynn's Pharmacy Inc.

🇺🇸

Griffin, Georgia, United States

Summerfield Pharmacy

🇺🇸

Riverview, Florida, United States

Goodrich Pharmacy

🇺🇸

Elk River, Minnesota, United States

Cub Pharmacy Number 1924

🇺🇸

St. Louis Park, Minnesota, United States

Countryside Pharmacy

🇺🇸

Savannah, Missouri, United States

Albers' Specialty Pharmacy

🇺🇸

Kansas City, Missouri, United States

Texas Road Pharmacy

🇺🇸

Monroe, New Jersey, United States

Phil's Pills, Inc.

🇺🇸

Albuquerque, New Mexico, United States

Total Health and Wellness Center of Taos

🇺🇸

Taos, New Mexico, United States

Kroger Pharmacy #342

🇺🇸

Cary, North Carolina, United States

Family Prescription Center

🇺🇸

Bethlehem, Pennsylvania, United States

Foothills Compounding Pharmacy

🇺🇸

Enumclaw, Washington, United States

The Medicine Shoppe

🇺🇸

Bountiful, Utah, United States

Northview Pharmacy

🇺🇸

Layton, Utah, United States

Ostrom Drugs

🇺🇸

Kenmore, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath